The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery
Open accessAbstract
Development of clinically relevant tumor model systems for glioblastoma multiforme (GBM) is important for advancement of basic and translational biology. One model that has gained wide acceptance in the neuro-oncology community is the primary xenograft model. This model entails the engraftment of patient tumor specimens into the flank of nude mice and subsequent serial passage of these tumors in the flank of mice. These tumors are then used to establish short-term explant cultures or intracranial xenografts. This unit describes detailed procedures for establishment, maintenance, and utilization of a primary GBM xenograft panel for the purpose of using them as tumor models for basic or translational studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We developed a TMZ/nutlin3a dosing regimen in an intracranial xenograft model using GBM10 cells, which were derived from a recurrent wild-type p53 GBM tumor that expresses high levels of the base excision repair (BER) protein apurinic/apyrimidinic endonuclease I (APE1) and MGMT.”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025
Pegg, A. E. (1990) · PubMed · Cited by 730
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N. L., O'Fallon, J. R., Schaefer, P., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 387
Self-citationGiannini, C., Sarkaria, J. N., Saito, A., Uhm, J. H., Galanis, E., Carlson, B. L., Schroeder, M. A., & James, C. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000821 · Cited by 326
Self-citationSarkaria, J. N., Carlson, B. L., Schroeder, M. A., Grogan, P., Brown, P. D., Giannini, C., Ballman, K. V., Kitange, G. J., Guha, A., Pandita, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2510 · Cited by 270
Self-citationLi, A., Walling, J., Kotliarov, Y., Steed, M. E., Ahn, S. J., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0280 · Cited by 264
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR
Pandita, A., Aldape, K., Zadeh, G. M., Guha, A., & James, C. D. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10300 · Cited by 212
Cited by
Sorted by citations
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L. A., Thompson, R. C., Müller, S., Knapp, S., & Wang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3066 · Cited by 305
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Chen, X., Zhang, M., Gan, H., Wang, H., Lee, J., Fang, D., Kitange, G. J., He, L., Hu, Z., Parney, I. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05373-4 · Cited by 270
Self-citationPurine metabolism regulates DNA repair and therapy resistance in glioblastoma
Zhou, W., Yao, Y., Scott, A. J., Wilder-Romans, K., Dresser, J., Werner, C. K., Sun, H., Pratt, D. W., Sajjakulnukit, P., Zhao, S. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17512-x · Cited by 251
Self-citationVaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0909 · Cited by 227
Self-citationStafford, J. H., Hirai, T., Deng, L., Chernikova, S. B., Urata, K., West, B. L., & Brown, J. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov272 · Cited by 233
Metadata
- Authors
- Carlson, B. L., Pokorny, J. L., Schroeder, M. A., & Sarkaria, J. N.
- Affiliations
- Mayo Clinic (US)
- Venue
- Current Protocols in Pharmacology
- Publisher
- Wiley
- Published
- 2011-03
- Volume
- 52
- Issue
- 1
- Pages
- Unit 14.16-Unit 14.16
- ISSN
- 1934-8282 (ISSN-L)
- 1934-8290
- PMC
- PMC3129784
- OpenAlex
- W1544655463
- Cited by
- 227
- References
- 24
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 21 · 2023: 18 · 2022: 16 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 18 · 2017: 21 · 2016: 13 · 2015: 17 · 2014: 9 · 2013: 9 · 2012: 9
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Protocols in Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA127716, CA108961, P50CA108961)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- glioblastoma, human tumor xenografts, nude mice, serial passage, intracranial xenograft, explant culture, drug discovery, translational oncology, tumor model establishment
- MeSH terms
- Animals, Disease Models, Animal, Glioblastoma, Humans, Mice, Nude, Xenograft Model Antitumor Assays, Mice, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
